Pediatrix Medical Group - MD Stock Forecast, Price & News

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Pediatrix Medical Group in the last twelve months. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" MD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MD, but not buy additional shares or sell existing shares.
View MD analyst ratings or view top-rated stocks.

4 brokers have issued 12-month price targets for Pediatrix Medical Group's stock. Their MD share price forecasts range from $16.00 to $31.00. On average, they expect the company's share price to reach $24.67 in the next year. This suggests a possible upside of 49.4% from the stock's current price.
View analysts price targets for MD or view top-rated stocks among Wall Street analysts.

Pediatrix Medical Group's stock was trading at $27.21 at the beginning of 2022. Since then, MD stock has decreased by 39.3% and is now trading at $16.51.
View the best growth stocks for 2022 here.

Pediatrix Medical Group saw a increase in short interest in August. As of August 31st, there was short interest totaling 4,610,000 shares, an increase of 21.6% from the August 15th total of 3,790,000 shares. Based on an average daily volume of 708,900 shares, the days-to-cover ratio is currently 6.5 days. Approximately 5.6% of the company's stock are short sold.
View Pediatrix Medical Group's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 27th 2022.
View our MD earnings forecast.

Pediatrix Medical Group, Inc. (NYSE:MD) released its quarterly earnings results on Thursday, August, 4th. The company reported $0.43 earnings per share for the quarter, meeting the consensus estimate of $0.43. The company earned $486 million during the quarter, compared to analysts' expectations of $491.54 million. Pediatrix Medical Group had a net margin of 4.30% and a trailing twelve-month return on equity of 16.15%. The business's revenue for the quarter was up 2.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.36 earnings per share.

6 employees have rated Pediatrix Medical Group Chief Executive Officer Mark S. Ordan on Glassdoor.com. Mark S. Ordan has an approval rating of 34% among the company's employees. This puts Mark S. Ordan in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Pediatrix Medical Group investors own include NVIDIA (NVDA), AbbVie (ABBV), QUALCOMM (QCOM), Gilead Sciences (GILD), Pfizer (PFE), AT&T (T), Walt Disney (DIS), Wells Fargo & Company (WFC), Exxon Mobil (XOM) and Advanced Micro Devices (AMD).

Pediatrix Medical Group trades on the New York Stock Exchange (NYSE) under the ticker symbol "MD."

Shares of MD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MD stock can currently be purchased for approximately $16.51.

Pediatrix Medical Group (NYSE:MD) has a market capitalization of $1.39 billion and generates $1.91 billion in revenue each year. The company earns $130.96 million in net income (profit) each year or $0.98 on an earnings per share basis.

The company employs 5,000 workers across the globe.

Pediatrix Medical Group's mailing address is 1301 CONCORD TERRACE, SUNRISE FL, 33323. The official website for the company is www.mednax.com. The company can be reached via phone at (954) 384-0175, via email at charles_lynch@mednax.com, or via fax at 954-838-9961.